Company intelligence / Profile preview
Stamford Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
Stamford Pharmaceuticals has demonstrated positive Phase 2 results for its lead gene therapy candidate SP‑002 in combination with vismodegib for multi-lesional and locally advanced basal cell carcinoma. The studies showed safety and efficacy signals, supporting further development into Phase 3 trials. The company is also advancing additional programs targeting other cutaneous cancers and solid tumors using its proprietary vector-drug conjugate platform[10][6][1].
- Therapeutic areas
- Oncology
- Modalities
- Gene therapyAdenovirus-based gene therapySmall molecule-drug conjugateVector-drug conjugateSmall molecule (for combination therapies)
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Stamford Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stamford Pharmaceuticals.